TIDMSBI
RNS Number : 6433N
SourceBio International PLC
01 October 2021
SourceBio International plc
("SourceBio", the "Company" or "the Group")
Grant of share options
SourceBio International plc (AIM: SBI), a leading international
provider of integrated state-of-the-art laboratory services and
products , announces that it has granted 4,750,000 share options to
Executive Directors and other employees under the Company's new
Executive Share Option Plan ("ESOP"), which the Company's Board
approved to establish following the passing of a resolution at the
Company's AGM in June.
The share options granted were proposed by the Remuneration
Committee and approved by the Board. In proposing these option
grants the Remuneration Committee was conscious that no options
have been granted in the past, in particular since Admission to AIM
in October 2020.
The number of shares under the options that have been granted
are as follows:
Jay LeCoque, Executive Chairman and Director 2,000,000
Tony Ratcliffe, Chief Financial Officer and Director 1,350,000
Other employees 1,400,000
The options will vest over three years in three equal annual
tranches subject to the Rules of the ESOP. For all share options to
become exercisable, the performance vesting condition requires a
share price of 200 pence or greater, representing a premium of 43%
to the closing mid-market price on 29 September 2021 of 140
pence.
For Jay LeCoque the share options have an exercise price of 162
pence per share, being the share price on Admission. This
represents a premium of 16% to the closing price of 140 pence on 29
September 2021. All other share options have an exercise price of
140 pence per share, being the closing price on 29 September
2021.
All the share options have a 10-year term from the date of grant
(subject to their earlier exercise or lapse in accordance with the
rules of the ESOP).
Following the grant of the share options outlined above, the
total share options outstanding will be 4,750,000 representing
approximately 6.4% of the 74,183,038 ordinary shares in issue.
Contacts:
SourceBio International plc www.sourcebiointernational.com
Jay LeCoque, Executive Chairman Via Walbrook PR
Tony Ratcliffe, Chief Financial
Officer
Liberum (Nominated Adviser and Broker) Tel: 020 3100 2000
Bidhi Bhoma / Richard Lindley /
Euan Brown
Walbrook PR Limited Tel: 020 7933 8780 or sourcebio@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07502
558 258
About SourceBio International plc
www.sourcebiointernational.com
SourceBio is a leading international provider of integrated
state-of-the-art laboratory services and products with clients in
the healthcare, clinical, life science research and biopharma
industries, with a focus on improving patient diagnosis, management
and care. Group revenues are derived from four core businesses
areas:
-- Infectious Disease Testing - a range of COVID-19 testing
services for commercial enterprises, private healthcare groups, NHS
and the DHSC. Utilising multiple technologies, SourceBio offers
screening, gold standard RT-PCR and whole genome sequencing
COVID-19 testing solutions and operates under ISO 15189
accreditation required by the DHSC. SourceBio also provides
employee testing solutions to industry, and direct to consumer home
test kits (including "Fit to Fly", "Test to Release" and "Day 2
& Day 8 International Travel" approved tests).
-- Healthcare Diagnostics - histopathology cancer screening and
clinical diagnostic services for the NHS and private healthcare
across the UK and Ireland.
-- Genomics - DNA sequencing services for pharmaceutical and
biotechnology companies, academia, contract research organisations
(CROs) and other research groups in the UK, Europe and North
America.
-- Stability Storage - shelf-life testing services and equipment
for pharmaceutical and biotechnology companies, contract
manufacturers and analytical testing companies from around the
world but primarily in the UK, Ireland and the USA.
More details on Group operations can be found here:
www.sourcebioscience.com .
SourceBio International plc (SBI) is listed on the AIM market of
the London Stock Exchange.
DEALING NOTIFICATION FORM
FOR USE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND
THEIR CLOSELY ASSOCIATED PERSONS
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Jay LeCoque
---------------------------------------------------------------------
2. Reason for the notification
---------------------------------------------------------------------
a) Position/status: Executive Chairman and Director
---------------------------------------------------------------------
b) Initial notification/Amendment: Initial Notification
---------------------------------------------------------------------
3. Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---------------------------------------------------------------------
a) Name: SourceBio International plc
---------------------------------------------------------------------
b) LEI: 213800KY4C9WU7WBW518
---------------------------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each place
where transactions have been conducted
---------------------------------------------------------------------
a) Description of the financial instrument, type of
instrument:
Ordinary shares of GBP0.0015 each
Identification code: GB00BKSB1674
---------------------------------------------------------------------
b) Nature of the transaction: Grant of options
---------------------------------------------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
162p 2,000,000
----------
---------------------------------------------------------------------
d) Aggregated information:
N/A - Single transaction
---------------------------------------------------------------------
e) Date of the transaction: 30 September 2021
---------------------------------------------------------------------
f) Place of the transaction: Outside trading venue
---------------------------------------------------------------------
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name: Tony Ratcliffe
---------------------------------------------------------------------
2. Reason for the notification
---------------------------------------------------------------------
a) Position/status: Chief Financial Officer and Director
---------------------------------------------------------------------
b) Initial notification/Amendment: Initial Notification
---------------------------------------------------------------------
3. Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
---------------------------------------------------------------------
a) Name: SourceBio International plc
---------------------------------------------------------------------
b) LEI: 213800KY4C9WU7WBW518
---------------------------------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type
of transaction; (iii) each date; and (iv) each place
where transactions have been conducted
---------------------------------------------------------------------
a) Description of the financial instrument, type of
instrument:
Ordinary shares of GBP0.0015 each
Identification code: GB00BKSB1674
---------------------------------------------------------------------
b) Nature of the transaction: Grant of options
---------------------------------------------------------------------
c) Price(s) and volume(s): Price(s) Volume(s)
140p 1,350,000
----------
---------------------------------------------------------------------
d) Aggregated information:
N/A - Single transaction
---------------------------------------------------------------------
e) Date of the transaction: 30 September 2021
---------------------------------------------------------------------
f) Place of the transaction: Outside trading venue
---------------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHLMMRTMTJJBLB
(END) Dow Jones Newswires
October 01, 2021 02:00 ET (06:00 GMT)
Sourcebio (LSE:SBI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Sourcebio (LSE:SBI)
Historical Stock Chart
From Dec 2023 to Dec 2024
